Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Myriad Genetics, Inc. (NASDAQ: MYGN) closed at $24.37 down -6.12% from its previous closing price of $25.96. In other words, the price has decreased by -$6.12 from its previous closing price. On the day, 0.71 million shares were traded. MYGN stock price reached its highest trading level at $26.52 during the session, while it also had its lowest trading level at $24.18.
Ratios:
For a deeper understanding of Myriad Genetics, Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.78 and its Current Ratio is at 1.96. In the meantime, Its Debt-to-Equity ratio is 0.19 whereas as Long-Term Debt/Eq ratio is at 0.18.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on September 19, 2024, initiated with a Equal-Weight rating and assigned the stock a target price of $32.
On August 28, 2024, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $35.
On June 27, 2024, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $29.Scotiabank initiated its Sector Outperform rating on June 27, 2024, with a $29 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 21 ’24 when Ancona Margaret bought 11,538 shares for $27.82 per share.
DIAZ PAUL J sold 15,000 shares of MYGN for $400,800 on Sep 11 ’24. The President and CEO now owns 977,378 shares after completing the transaction at $26.72 per share. On Sep 11 ’24, another insider, Muzzey Dale, who serves as the Chief Scientific Officer of the company, sold 2,100 shares for $26.17 each. As a result, the insider received 54,961 and left with 108,013 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MYGN now has a Market Capitalization of 2213293312 and an Enterprise Value of 2259291904. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.76 while its Price-to-Book (P/B) ratio in mrq is 2.99. Its current Enterprise Value per Revenue stands at 2.816 whereas that against EBITDA is -46.108.
Stock Price History:
Over the past 52 weeks, MYGN has reached a high of $29.30, while it has fallen to a 52-week low of $13.82. The 50-Day Moving Average of the stock is -10.48%, while the 200-Day Moving Average is calculated to be 3.51%.
Shares Statistics:
For the past three months, MYGN has traded an average of 737.43K shares per day and 576190 over the past ten days. A total of 89.90M shares are outstanding, with a floating share count of 87.38M. Insiders hold about 3.79% of the company’s shares, while institutions hold 102.08% stake in the company. Shares short for MYGN as of 1726185600 were 3939214 with a Short Ratio of 5.34, compared to 1723680000 on 3876782. Therefore, it implies a Short% of Shares Outstanding of 3939214 and a Short% of Float of 6.0700003.
